Office-Use Compounding Request at a 503A Pharmacy
A dermatology clinic asks your 503A community pharmacy to compound 200 units of 0.1% triamcinolone acetonide cream in 30-g tubes for office use. The clinic wants to keep them on a shelf and dispense to patients as needed. You can obtain FDA-approved triamcinolone acetonide 0.1% cream from your wholesaler. The clinic does not provide patient names. Your state follows the federal patient-specific prescription requirement for 503A pharmacies and does not allow office-use distribution without a patient-specific prescription.
1. Can you accept the clinic's request as a 503A pharmacy?
Read the worked answer
No. A 503A pharmacy compounds pursuant to a patient-specific prescription, and the clinic has provided no patients. Office-use distribution without patient-specific prescriptions is a 503B outsourcing-facility activity, not a 503A activity. There is also an essentially-a-copy problem: FDA-approved 0.1% triamcinolone acetonide cream is commercially available, and 200 units for shelf stock is regular or significant-quantity compounding of a copy. The 503A exemption does not cover this request.
2. What if the clinic provided a prescription for each patient?
Read the worked answer
Patient-specific prescriptions remove the office-use problem but not the essentially-a-copy problem. A 503A pharmacy may not compound a drug that is essentially a copy of a commercially available drug, regularly or in significant quantities, unless an exception applies, such as a documented clinical difference for an identified patient. You would need to evaluate whether the compounded preparation is for a genuine patient-specific need and whether the quantity and frequency make it essentially a copy. Document the clinical rationale and the prescription for each patient.
3. What pathway would allow the clinic to obtain office-use compounded product?
Read the worked answer
The clinic would need to obtain the product from a registered 503B outsourcing facility, which can compound without patient-specific prescriptions but must comply with 503B conditions, including cGMP, adverse-event reporting, and restrictions on compounding essentially a copy of a commercially available drug unless a shortage-list exception applies. Alternatively, the clinic could use the FDA-approved commercial cream. Your 503A pharmacy should not act as an office-use distributor under these facts.